Brief: CanSino Biologics' COVID Recombinant Vaccine Gets Registration In Hong Kong
May 9 (Reuters) - CanSino Biologics Inc 6185.HK :
* SAYS ITS COVID-19 RECOMBINANT VACCINE GETS REGISTERED WITH
HONG
KONG'S PHARMACY & POISONS BOARD
Source text 1
Source text 2
Further company coverage: 6185.HK
(Reporting by Hong Kong newsroom)
((meg.shen@thomsonreuters.com; 852-39525805;))
Recent news on Cansino Biologics
See all newsBrief: CanSino Biologics Says China's NMPA Granted Priority Review Status To NDA For TD5CP Adolescent, Adult
Brief: CanSino Biologics Reports Widened Net Loss For Q1
Brief: CanSino Biologics Says 2025 Net Profit At 27.9 Million Yuan
Brief: CanSino Biologics Prelim 2025 Net Profit At 27.9 Million Yuan
Brief: CanSino Biologics Expects To Have Returned to Net Profit In 2025